Cellular therapies

Bone marrow transplantation / blood stem cell transplantation

The Hannover Medical School is one of the largest centers in Germany for bone marrow and blood stem cell transplants. It is the only center in Lower Saxony that offers all types of transplants for children and adults.

CAR T-cell therapy is an immunotherapy in which genetically modified T-cells (so-called CAR T-cells) with synthetic antigen-specific receptors are used.

You can find information about our CAR T-cell special consultation hours here.

Approved indications

For adult patients (according to current prescribing information) with relapsed or refractory hematologic neoplasms:

Diffuse large B-cell lymphoma (DLBCL), highly malignant B-cell lymphoma (HGBCL), primary mediastinal large B-cell lymphoma (PMBCL)

• Recurrence within 12 months after completion of first-line chemoimmunotherapy or refractory to this therapy
• Recurrence after two or more lines of systemic therapy)

Follicular lymphoma

• up to grade 3A: Recurrence after two or more lines of systemic therapy
• Grade 3B: Recurrence within 12 months after completion of first-line chemoimmunotherapy or refractory to this therapy; recurrence after two or more lines of systemic therapy

Mantle cell lymphoma

• after two or more lines of systemic therapy that include a Bruton's tyrosine kinase (BTK) inhibitor

B-ALL

• up to 25 years: relapse after transplantation, or second or later relapse
• from 26 years of age: relapsed or refractory B-cell precursor ALL

Multiple myeloma

• Disease progression during at least one therapy with immunomodulator and a proteasome inhibitor incl. refractory to lenalidomide
• Disease progression during at least two previous therapies, including immunomodulator, proteasome inhibitor and an anti-CD38 antibody

Experimental indications

For adult patients with therapy-refractory autoimmune diseases (individual therapeutic trial after approval of reimbursement by the health insurance company or as part of clinical trials):

• Systemic lupus erythematosus
• myositis
• Systemic sclerosis
• Rheumatoid arthritis
• Multiple sclerosis
• Myasthenia gravis
• Acquired hemophilia A

Clinical portfolio

• Preparation, implementation and follow-up after CAR T-cell therapy
• Second opinions for the evaluation of CAR T-cell therapy
• Advice in the relapse situation (relapse therapy incl. bispecific antibodies vs. CAR T-cell therapy)
• Treatment in the context of clinical studies

Tabelecleucel (Ebvallo®)

Tabelecleucel is an allogeneic EBV-specific T-cell product used in the treatment of relapsed or refractory Epstein-Barr virus positive post-transplant lymphoproliferative disease (EBV+ PTLD).

Approved indications

Tabelecleucel (Ebvallo®) is used as monotherapy for the treatment of adult and pediatric patients 2 years of age and older with relapsed or refractory Epstein-Barr virus positive post-transplant lymphoproliferative disease (EBV+ PTLD) who have received at least one prior treatment. For solid organ transplant patients, prior therapy includes chemotherapy, unless chemotherapy is deemed inappropriate.

Clinical portfolio

• Preparation, implementation and follow-up of therapy with tabelecleucel
• Second opinions for the evaluation of therapy with tabelecleucel